Molecular basis of resistance to proteasome inhibitors in hematological malignancies

Over the past decade, the proteasome inhibitor bortezomib (Velcade) has not only gained a cornerstone position in the treatment of hematological malignancies, particularly multiple myeloma and mantle cell lymphoma, but also in experimental therapeutics of acute leukemia. However, the therapeutic eff...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug resistance updates Jg. 18; S. 18 - 35
Hauptverfasser:	Niewerth, Denise, Jansen, Gerrit, Assaraf, Yehuda G., Zweegman, Sonja, Kaspers, Gertjan J.L., Cloos, Jacqueline
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Scotland Elsevier Ltd 01.01.2015
Schlagworte:	Animals Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Boronic Acids - adverse effects Boronic Acids - pharmacology Bortezomib Drug Resistance, Neoplasm Hematologic Neoplasms - drug therapy Hematologic Neoplasms - pathology Hematology, Oncology and Palliative Medicine Humans Infectious Disease Leukemia Multiple myeloma Proteasome inhibitor Proteasome Inhibitors - pharmacology Pyrazines - adverse effects Pyrazines - pharmacology Resistance Resistance Bortezomib Proteasome inhibitor Leukemia Multiple myeloma
ISSN:	1368-7646, 1532-2084, 1532-2084
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!